EGFR and non-small cell lung carcinoma: Another potential use of these findings is that Osimertinib could be considered a first-line treatment of EGFR mutation-positive advanced NSCLC tumors, particularly advanced NSCLC patients with T790M mutation-positive tumors, as the EGFR T790M mutation is the most common genetic change after resistance to first-line EGFR-TKI therapy.